TABLE 4.
IC50s for CD4-2G12 constructs compared with 2G12-only and CD4-only reagents
| Env | Clade | IC50 (nM)a |
||||
|---|---|---|---|---|---|---|
| Monomer |
Dimer |
CD4- IgG2 | ||||
| 2G12 | CD4HC-IgG2G12 | 2G12 | CD4HC-IgG2G12 | |||
| PVO.4 | B | 33* | 4.2* | <0.17* | 0.30* | 27* |
| SC422661.8 | B | 140 | 4.4 | 0.38 | 0.46 | 7.3 |
| QH0692.42 | B | 72 | 1.8 | 0.71 | 0.60 | 0.83 |
| TRO.11 | B | 13 | 6.8 | 0.11 | 0.63 | 92 |
| Du156.12 | C | >670* | >530* | >330* | >260* | 40* |
| Du172.17 | C | >670 | 6.3 | >330 | 1.1 | 2.5 |
| Geometric mean | 110 | 9.5 | 2.9 | 1.6 | 11 | |
| Arithmetic mean | 270 | 92 | 110 | 44 | 28 | |
a
Results are from in-house neutralization assays except for values marked with an asterisk, which are from CAVD core neutralization facility assays. In calculating average IC50s, measurements outside of the range of the assay (indicated by a > symbol) were assigned to that limiting value.